Alerta

METHODS FOR INHIBITING MACROPHAGE NEUROTOXICITY

Resumen de: US20260276627A1

0000 Provided is a method for inhibiting macrophage neurotoxicity, the method comprising increasing expression of Aurora kinase in macrophages, wherein the Aurora kinase includes AURKA, AURKB, or a combination thereof. The expression may be increased by co-culturing the macrophages with neurons such as dorsal root ganglion sensory neurons, hippocampal neurons, dopaminergic neurons, motor neurons, cerebellar granule cells, thalamic neurons, or spinal cord neurons.

Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis

Resumen de: US20260272907A1

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.

SIMULATION DEVICE TO GENERATE HYBRID IN-VITRO/IN-SILICO NEURONAL POPULATIONS IN A CLOSED LOOP WITH MULTI-ELECTRODE ARRAYS

Resumen de: WO2026190495A1

The present invention refers to the field of in-vitro neural network stimulation, and particularly to devices that utilize cell cultures on multi-electrode arrays (MEAs) for investigating neuronal activity in research and drug testing applications. The invention consists of a closed loop system wherein a computational model stimulates via the electrodes of a MEA, cultured neurons on top of the MEA in order to produce disease- like activity states. The produced activity feeds back to the computational model, in real or periodic time, producing a hybrid neuronal population that can be used for drug screening. The respective method for the application of the abovementioned system is also disclosed.

METHODS OF DETECTING, TREATING, AMELIORATING, AND/OR PREVENTING COGNITIVE DECLINE

Resumen de: WO2026193298A1

Described herein is a method of diagnosing or predicting the risk of cognitive decline in a subject, and/or stratifying the subject according to the risk. The method comprises determining a profile of the subject; and predicting the risk based on the profile, or stratifying the subject to a high risk group or a low risk group based on the predicted risk. The profile comprises blood pressure; and the level of homocysteine (Hyc) in a biological sample from the subject. Also described herein is a method of treating, ameliorating, and/or preventing cognitive decline in the subject based on the prediction of the risk.

ALPHA-SYNUCLEIN ANTIBODIES FOR USE IN DIAGNOSTIC ASSAYS AND TREATMENT OF ALPHA-SYNUCLEINOPATHIES

Resumen de: WO2026190230A1

The present invention relates to alpha-synuclein antibodies which are useful in diagnostic assays for detecting aggregates, oligomers and fibrillar forms of alpha- synuclein in patient samples. These antibodies enable diagnosis and efficient treatment of alpha-synucleinopathies such as Parkinson's Disease (PD) or Multiple System Atrophy (MSA) patients by assessing and monitoring the pathological alpha-synuclein levels in patients.

ANALYTE SIGNATURES OF LONG COVID AND USES THEREOF

Resumen de: WO2026193026A1

The invention provides methods for determining if a subject suffering from SARS-CoV-2 infection is susceptible to developing fibromyalgia. Also provided herein are methods for identifying if a subject possesses a disease or condition characterized or caused by an immune system deficiency, such as chronic pain or fatigue, long COVID or interstitial cystitis (IC).

METHODS OF ADENOVIRAL GENE THERAPY

Resumen de: WO2026193412A1

Among other things, the present disclosure provides adenoviral vectors, genomes, and methods of use thereof. In some embodiments, the present disclosure provides methods of in vivo gene therapy comprising administration of an adenoviral payload vector and an adenoviral integration vector. The present disclosure provides, among other things, compositions comprising an adenoviral payload vector and an adenoviral integration vector for use in, e.g., methods of in vivo gene therapy. In some embodiments, the present disclosure provides adenoviral vectors, genomes, and compositions thereof comprising a therapeutic sequence, e.g., a nucleic acid sequence encoding a CYBB therapeutic polypeptide. In some embodiments, the present disclosure provides methods of treating various conditions, disorders, and diseases, e.g., chronic granulomatous disease.

METHODS FOR SINGLE BIOLOGICAL NANOPARTICLE ANALYSIS

Resumen de: EP4807366A2

0001 The present disclosure relates to methods, systems, and devices for performing analyses of biological nanoparticles. More specifically, the present disclosure relates to methods, systems, and devices for performing single biological nanoparticle size determination on a sample while the biological nanoparticle is in transit through a microfluidic chip. In other aspects, the present disclosure relates to methods, systems, and devices for selectively capturing biological nanoparticles on a coated planar surface, the capturing being facilitated by centrifugation.

NOVEL METHOD

Resumen de: WO2025099457A2

The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.

ナノザイムベースのラテラルフローアッセイおよびデバイス

Resumen de: WO2025041169A1

The present invention provides a kit, a device and an in-vitro assay based on a nanozyme-based lateral flow assay utilizing para-phenylenediamine of optimal concentration 0.1mM to 10mM as a chromogenic substrate for catalytically active aptamer-conjugated gold-nanozyme, which enhances sensitivity. The chromogenic substrate produces a robust brown color upon oxidation by catalytically active nanomaterial. The brown color remains stable for weeks and presents high contrast against the background. This overcomes the limitations of ordinary LFA in detecting analytes present at critical levels that are below microgram per milliliter, often resulting in false negative results. This provides a versatile and high-sensitive point-of-care diagnostic technique for rapid screening of infectious disease antigens and the detection of biomarkers for diseases such as cancer, cardiac and neurodegenerative diseases.

ほぼ完全長の免疫グロブリン重鎖および軽鎖レパトアの単一分子解析のための方法

Resumen de: WO2025049921A1

The present disclosure provides a near full-length long read AIRR-seq (FLAIRR-Seq) method that utilizes targeted amplification by 5' rapid amplification of cDNA ends (RACE), combined with single molecule, real-time sequencing to generate highly accurate immunoglobulin (Ig) heavy chain and light chain transcripts.

ＴＲＥＧ細胞を標的とするための方法及び組成物

Resumen de: MX2025010847A

The antibody NEO-201 is shown to bind to Treg cells, and its use in targeting Treg cells is described. NEO-201 may be used for isolation, detection, or purification of active Treg cells and also to kill Treg cells. Therapeutic methods and combination therapies using NEO-201 optionally in combination with another agent are described.

生体分子の超高感度検出のための単一分子アッセイ

Resumen de: WO2021262706A1

Provided herein are assays that provide digital measurement methods to detect proteins and other biomolecules, e.g., at low- to mid-attomolar concentrations.

一种检测老年痴呆的试剂盒及其应用

Resumen de: CN122754497A

0001 本发明涉及生物医学技术领域，具体而言，本发明涉及一种检测老年痴呆的试剂盒及其应用。该试剂盒包含针对β‑淀粉样蛋白Aβ42和Aβ40的特异性单克隆抗体，其中抗人Aβ42单克隆抗体通过免疫Balb/c小鼠、细胞融合和杂交瘤筛选制备，其轻重链可变区序列如SEQ No.1‑6所示；抗人Aβ40单克隆抗体采用类似方法制备。试剂盒还包括预包被酶标板、标准品和酶标记检测抗体。通过ELISA方法检测患者外周血血清中Aβ42和Aβ40的水平，并计算Aβ42/Aβ40比值，用于阿尔兹海默症的诊断。该试剂盒具有灵敏特异、快速便捷、易于操作等特点，能有效区分阿尔兹海默症患者和抑郁症患者，适用于体外预筛查和诊断。

アミロイド原線維凝集物検出用ペプチド

Resumen de: WO2025046049A1

The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.

一种有机化合物及其制备方法、作为探针的应用

Resumen de: CN122749439A

本申请公开了一种有机化合物及其制备方法、作为探针的应用，属于探针领域。有机化合物具有式I所示的结构其中，arene代表芳香杂环，选自萘环、喹喔啉、苯并噻二唑中的一种；R1选自羟基、甲氧基、哌啶、吗啉、久洛尼定、氰基、硝基中的一种；R2选自氯原子、溴原子、碘原子中的一种。该探针在具有淀粉样变蛋白靶向能力的同时，在体外淀粉样模型蛋白中也表现出选择性标记的特点，可以用于阿尔茨海默病模型小鼠淀粉样沉积物的组分分析，弥补了领域内缺乏对阿尔茨海默病致病蛋白的组分分析这一空白。

一种与无序蛋白强啡肽A特异性结合的人工从头设计蛋白

Resumen de: CN122749696A

0001 本发明涉及一种与强啡肽A特异性结合的人工从头设计蛋白，所述蛋白质的氨基酸序列如SEQ ID NO:1所示。本发明针对强啡肽A具有高度柔性和动态构象的特点，通过人工从头设计方法构建具有特异性识别界面的结合蛋白，可对强啡肽A的特定序列区域或优势构象进行有效识别与结合，突破了传统“锁钥模型”难以适用于无序蛋白识别的限制。

血管内皮细胞中SIRT7的应用、筛选药物方法及药物组合物、试剂盒、模型构建方法

Resumen de: CN122750834A

本发明提供一种血管内皮细胞中SIRT7的应用、筛选药物方法及药物组合物、试剂盒、模型构建方法。血管内皮细胞中的SIRT7作为药物靶点在制备预防、延缓或治疗脑衰老和/或血管性痴呆的药物中的应用。血管内皮细胞中的SIRT7作为生物标志物在制备用于评估脑衰老程度或血管性痴呆风险的诊断试剂或试剂盒中的应用。

HCN1 CNBD - Novel Indazole-Pyridine Compounds Binding to HCN1 Channel CNBD Domain and Pharmaceutical Compositions Containing the Same for Treatment of Alzheimer's Disease

Resumen de: KR20260135747A

본 발명은 HCN1 채널의 CNBD 도메인에 특이적으로 결합하는 세계 최초의 소분자 개방제(ind_5F_3pyr, 5-플루오로-1H-인다졸-3-일-피리딘-3-일)에 관한 것이다. 알츠하이머병에서 HCN1 채널 발현이 감소하여 신경 흥분성 이상이 발생하며, 기존 HCN 약물은 모두 차단제로서 이를 해결할 수 없다. 본 발명의 화합물은 HCN1 CNBD에 cAMP보다 강하게 결합하고(ΔG = -8.08 vs -7.51 kcal/mol), 열린 상태를 안정화하며(apo ΔG = -8.32), 혈액뇌장벽을 투과하고(MW 213, TPSA 57), TRIP8b 대체를 통한 뇌 선택성을 달성한다. 119개 후보 중 가상 스크리닝과 분자동역학으로 동정되었다. JPEGpat00001.jpg5157

抗人Aβ1-40和Aβ1-42的单克隆抗体和基于其的产品以及应用

Resumen de: CN122726299A

0001 本发明公开了一种抗人Aβ1‑40和Aβ1‑42的单克隆抗体和基于其的产品以及应用，属于单克隆抗体技术领域。所述抗体包括轻链和重链，轻链属于kappa型，重链属于IgG2b型；其轻链可变区的3个互补决定区的氨基酸序列分别如SEQ ID No.1、2、3所示；重链可变区的3个互补决定区的氨基酸序列分别如SEQ ID No.9、10、11所示。该抗体经由化学合成的人Aβ1‑20短肽偶联KLH作为抗原免疫小鼠后，经融合和数次克隆化筛选获得，能同时高效特异性识别人Aβ1‑40和Aβ1‑42，不结合BSA、KLH‑p‑Tau217、NFL等无关蛋白，平衡解离常数达皮摩尔级（Kd ≈ 51 pM），可用于人Aβ1‑40和Aβ1‑42的定量检测与体外诊断试剂盒开发，同时在Aβ相关疾病的抗体治疗中具有应用潜力。

一种β-淀粉样寡聚物的检测方法及分子探针

Resumen de: CN122726282A

本发明涉及生物医学领域，具体而言，涉及一种β‑淀粉样寡聚物的检测方法及分子探针。该分子探针的氨基酸序列中包括免疫球蛋白样受体LilrB2胞外结构域的D1D2蛋白氨基酸片段，β‑淀粉样寡聚物包括散发性阿尔兹海默症β‑淀粉样寡聚物突变体，还包括家族性阿尔兹海默症β‑淀粉样寡聚物突变体。该检测方法可对阿尔茨海默病早期阶段的精准诊断，具有广谱识别能力，对Aβ寡聚物具有良好的选择性和特异性，可对脑组织、脑脊液和血液等样本进行体外检测，实现无创早期诊断，具有广阔的临床转化前景。

维卡格雷或其药用盐在制备cGAS乙酰化抑制剂及相关药物中的用途

Resumen de: CN122721423A

0001 本发明属于生物医药技术领域，公开了维卡格雷或其药用盐在制备环鸟腺苷合成酶（cGAS）乙酰化抑制剂以及在制备用于治疗自身免疫性疾病和神经退行性疾病的药物中的用途。

一种化合物及其制备方法、作为探针的应用

Resumen de: CN122726026A

0001 本申请公开了一种化合物及其制备方法、作为探针的应用，属于探针领域。所述化合物的结构式为式I所示 该探针不仅具备淀粉样蛋白的靶向能力，能够特异性结合淀粉样蛋白，还能够在硼酸存在的条件下实现对淀粉样蛋白的选择性标记。可用于神经退行性疾病模型等多种淀粉样蛋白相关疾病中沉积蛋白的组分鉴定。

플라스말로겐의 정량방법 및 플라스말로겐의 정량용 키트

Resumen de: CN122319365A

Disclosed is a method for quantifying plasmalogen, which comprises: a measurement sample preparation step for obtaining a measurement sample by mixing a sample containing a protein and plasmalogen with a Schiff reagent; a control sample preparation step of mixing the test sample with the solvent of the Schiff reagent to obtain a control sample; a measurement step for measuring the degree of the first optical property of the measurement sample and the degree of the optical property of the control sample after the reaction of an aldehyde generated from the vinyl ether bond of the plasmalogen and the Schiff reagent; and a determination step for determining the concentration of the plasmalogen in the sample by comparing the degree of correction, which is obtained by correcting the degree of the first optical property using the degree of the optical property of the control sample, with the degree of the second optical property of a standard sample containing a Schiff reagent and a plasmalogen having a known concentration, and determining the concentration of the plasmalogen in the sample. The degree of the second optical property is the degree of reaction of the Schiff reagent with the aldehyde generated by the vinyl ether linkage of the plasmalogen.

基于白质骨架连续谱坐标的α-突触核蛋白病定位方法

Nº publicación: CN122731146A 11/09/2026

Solicitante:

首都医科大学附属北京友谊医院

Resumen de: CN122731146A

本发明公开了一种基于白质骨架连续谱坐标的α‑突触核蛋白病定位方法。该方法包括建模阶段与应用阶段：建模阶段将多壳层扩散磁共振的多个微结构参数统一投射至白质骨架空间，以预设的健康‑前驱‑临床连续谱顺序为约束，结合多参数排他式筛选规则识别阶段敏感白质簇，并构建以健康组与临床期组中心向量连线为连续谱主轴的参考轴及坐标映射规则；应用阶段将待评估对象经相同处理后的特征投影至该主轴，输出连续谱坐标值、阶段偏移量及阶段邻近度。本发明能够在单次横断面扫描下实现个体在疾病连续谱中的定量定位，克服了现有技术依赖纵向数据或离散状态判定的局限，可以广泛应用于α‑突触核蛋白病的早期识别与个体化评估。